SCHEMBL2716640

SCHEMBL2716640

NC(=O)c1cnccc1Nc1ccc2ncccc2c1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SYK P43405 6/20 0.58
MAPK8 P45983 1/20 0.53
NPC1 O15118 5/20 0.52
POLB P06746 2/20 0.52
MEN1 O00255 1/20 0.52
MAPT P10636 1/20 0.52
KMT2A Q03164 1/20 0.52
MAPK9 P45984 1/20 0.49
MAPK10 P53779 1/20 0.49
ALDH1A1 P00352 1/20 0.48
CYP1A2 P05177 1/20 0.48
CYP3A4 P08684 1/20 0.48
TSHR P16473 1/20 0.48
HSD17B10 Q99714 1/20 0.48
PABPC1 P11940 1/20 0.47
RAB9A P51151 4/20 0.46
TGFBR1 P36897 1/20 0.46
HTT P42858 1/20 0.45
SIRT2 Q8IXJ6 1/20 0.45
EGFR P00533 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2715880 0.90 MAPK9 (0.49) SYKMAPK8MEN1KMT2AMAPK9
SCHEMBL2713225 0.86 RAB9A (0.53) SYKNPC1POLBMAPTMAPK9
SCHEMBL3959568 0.81 TGFBR1 (0.43) SYKMAPK8NPC1MAPK9MAPK10
SCHEMBL2717397 0.81 MAPK9 (0.51) MAPK9MAPK10TGFBR1HTTSIRT2
SCHEMBL2717012 0.81 MAPK9 (0.51) MAPK9MAPK10SIRT2TNIK
SCHEMBL16657361 0.81 EGFR (0.51) SYKMAPK8NPC1POLBMEN1
SCHEMBL2716637 0.80 NPC1 (0.63) SYKMAPK8NPC1POLBMEN1
SCHEMBL2714846 0.77 SIRT2 (0.53) MAPK8NPC1MEN1KMT2AALDH1A1
SCHEMBL16202734 0.76 SYK (0.66) SYKMAPK8NPC1POLBMEN1
SCHEMBL30115310 0.76 EGFR (0.57) SYKNPC1RAB9AEGFRTNIK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2635556-A2 BENZAMIDES AND NICOTINAMIDES AS SYK MODULATORS Portola Pharmaceuticals, Inc. (US) 2013-09-11 EP claimed
WO-2012061418-A2 BENZAMIDES AND NICOTINAMIDES AS SYK MODULATORS PORTOLA PHARMACEUTICALS, INC. (US) 2012-05-10 WO claimed
US-8895585-B2 Nicotinamide derivative or salt thereof FUJIFILM CORPORATION (JP) 2014-11-25 US disclosed
US-8809371-B2 2014-08-19 US disclosed
US-8772320-B2 2014-07-08 US disclosed
US-20130116430-A1 NOVEL NICOTINAMIDE DERIVATIVE OR SALT THEREOF FUJIFILM CORPORATION (JP) 2013-05-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130116430-A1 NOVEL NICOTINAMIDE DERIVATIVE OR SALT THEREOF SYK, CD38, BTK SYK 1/4885MAPK8 838/4885NPC1 1367/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.